Coating construct with enhanced interfacial compatibility

• US 20080095918A1
• Filed: 06/14/2006
• Published: 04/24/2008
• Est. Priority Date: 06/14/2006
• Status: Abandoned Application

• Current Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Kleiner, Lothar W., Hossainy, Syed Faiyaz Ahmed, DesNoyer, Jessica Renee
• Application Number:
  US11/453,419
• Publication Number:
  US 20080095918A1
• Time in Patent Office: Days
• US Class Current: 427/2.24
• CPC Class Codes: A61L 2420/02 Methods for coating medical devices
• CPC Class Codes: A61L 2420/08 Coatings comprising two or more layers
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: C08L 27/12 containing fluorine atoms
• CPC Class Codes: C08L 27/18 Homopolymers or copolymers or tetrafluoroethene
• CPC Class Codes: C08L 77/12 Polyester-amides
• CPC Class Codes: Y10T 428/3154 Of fluorinated addition polymer from unsaturated monomers

Abstract

The present invention provides a method of forming a coating on a medical device having a topcoat and a basecoat and an improved compatibility between a topcoat and a basecoat on the medical device.

Claims

1. A method comprising:

preparing a topcoat formulation comprising a topcoat polymer and a solvent, and

applying the topcoat onto a basecoat of a medical device,

wherein the solvent is capable of

dissolving the topcoat polymer,

dissolving, plasticizing or swelling the top layer of the basecoat and

wherein the interfacial compatibility between the topcoat and the basecoat is improved.

2. The method of claim 1, wherein the topcoat comprises a poly(ester amide) (PEA) polymer.

3. The method of claim 1, wherein the basecoat comprises a fluoropolymer.

4. The method of claim 2, wherein the basecoat comprises poly(vinylidene-co-hexafluoropropene) (PVDF-HFP).

5. The method of claim 1, wherein the solvent comprises two or more components.

6. The method of claim 5, wherein the solvent comprises dimethyl acetamide (DMAc), cyclohexanone, an alcohol, CH₂Cl₂, chloroform, dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), trichloroethane, tetrachloroethane, acetone, tetrahydrofuran (THF), dioxane, toluene, ethyl acetate, methyl ethyl ketone (MEK), acetonitrile, or combinations of these.

7. The method of claim 6, wherein the solvent comprises a mixture of DMAc and methanol, a mixture of DMAc and ethanol, a mixture of DMAc and 1,4-butan-di-ol, a mixture of cyclohexanone and methanol, a mixture of cyclohexanone and ethanol, or a mixture of cyclohexanone and 1,4-butan-di-ol.

8. The method of claim 7, wherein the solvent comprises two components having a ratio ranging from about 10:

90 to about 90;

10.

9. The method of claim 1, wherein the basecoat comprises a bioactive agent.

10. The method of claim 9, wherein the bioactive agent comprises a component selected from paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), clobetasol, pimecrolimus, imatinib mesylate, midostaurin, prodrugs thereof, co-drugs thereof, or combinations of these.

11. The method of claim 9, wherein the medical device is a stent.

12. The method of claim 9, wherein the medical device is a bioabsorbable stent.

27. A coating on a medical device formed according to the method of claim 1 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

28. A coating on a medical device formed according to the method of claim 4 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

29. A coating on a medical device formed according to the method of claim 9 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

30. A coating on a medical device formed according to the method of claim 11 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

31. A coating on a medical device formed according to the method of claim 11 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

39. A method of treating a disorder in a patient comprising implanting in the patient a medical device with the coating of claim 27, wherein the disorder is at least one of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

40. A method of treating a disorder in a patient comprising implanting in the patient a medical device with the coating of claim 31, wherein the disorder is at least one of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

42. The method of claim 1, wherein the basecoat comprises a bioactive agent provided that the bioactive agent is not actinomycin.

13. A method comprising:

priming a basecoat on a medical device with a blank solvent spray, and

applying a topcoat formulation to the primed basecoat,

wherein the interfacial compatibility between the topcoat and the basecoat is improved.

14. The method of claim 13, wherein the basecoat comprises a fluoropolymer, and

wherein the topcoat comprises a PEA polymer.

15. The method of claim 14, wherein the fluoropolymer is PVDF-HFP.

16. The method of claim 14, wherein the basecoat comprises a bioactive agent.

17. The method of claim 16, wherein the bioactive agent comprises a component selected from paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), clobetasol, pimecrolimus, imatinib mesylate, midostaurin, prodrugs thereof, co-drugs thereof, or combinations of these.

18. The method of claim 16, wherein the medical device is a stent.

19. The method of claim 16, wherein the medical device is a bioabsorbable stent.

32. A coating on a medical device formed according to the method of claim 15 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

33. A coating on a medical device formed according to the method of claim 16 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

34. A coating on a medical device formed according to the method of claim 18 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

43. The method of claim 14, wherein the basecoat comprises a bioactive agent provided that the bioactive agent is not actinomycin.

20. A method comprising:

exposing a basecoat of a medical device to a solvent-rich atmosphere comprising a solvent capable of plasticizing or absorbing into the top layer of the basecoat, and

applying a topcoat formulation to the basecoat,

wherein the topcoat and the basecoat have an improved interfacial compatibility.

21. The method of claim 20, wherein the basecoat comprises a fluoropolymer, and

wherein the topcoat comprises a PEA polymer.

22. The method of claim 21, wherein the fluoropolymer is PVDF-HFP.

23. The method of claim 21, wherein the basecoat comprises a bioactive agent.

24. The method of claim 23, wherein the bioactive agent comprises a component selected from paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), clobetasol, pimecrolimus, imatinib mesylate, midostaurin, prodrugs thereof, co-drugs thereof, or combinations of these.

25. The method of claim 23, wherein the medical device is a stent.

26. The method of claim 23, wherein the medical device is a bioabsorbable stent.

35. A coating on a medical device formed according to the method of claim 20 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

36. A coating on a medical device formed according to the method of claim 22 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

37. A coating on a medical device formed according to the method of claim 23 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

38. A coating on a medical device formed according to the method of claim 25 comprising a basecoat portion and a topcoat portion with an improved interfacial compatibility between the topcoat and basecoat portions.

41. A method of treating a disorder in a patient comprising implanting in the patient a medical device with the coating of claim 35, wherein the disorder is at least one of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.